Cargando…
CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives or false n...
Autores principales: | Watanabe, Masayuki, Higashi, Tomohito, Ozeki, Kana, Higashi, Atsuko Y., Sugimoto, Kotaro, Mine, Hayato, Takagi, Hironori, Ozaki, Yuki, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki, Chiba, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206149/ https://www.ncbi.nlm.nih.gov/pubmed/34131154 http://dx.doi.org/10.1038/s41598-021-91464-0 |
Ejemplares similares
-
Our experience of lung resection in patients who decline blood transfusion for religious reasons
por: Takagi, Hironori, et al.
Publicado: (2021) -
Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
por: Okabe, Naoyuki, et al.
Publicado: (2021) -
Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report
por: Watanabe, Masayuki, et al.
Publicado: (2022) -
Thoracoscopic resection of posterior mediastinal paraganglioma: perioperative management and surgical tips
por: Matsumura, Yuki, et al.
Publicado: (2022) -
A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
por: Matsumura, Yuki, et al.
Publicado: (2021)